Advances in surface plasmon resonance–based biosensor technologies for cancer biomarker detection

Azzouz, Abdelmonaim; Hejji, Lamia; Kim, Ki‐Hyun; Kukkar, Deepak; Souhail, Badredine; Bhardwaj, Neha; Brown, Richard; Zhang, Wei

doi:10.1016/j.bios.2021.113767

Cited by 82 publications

(41 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, numerous methods have been proposed for glycoprotein detection. 5,6 Relative to dynamic light scattering (DLS), 4 fluorescence, 7,8 surface-enhanced Raman scattering (SERS), 2 colorimetry, 9 mass spectrometry (MS), 10 surface plasmon resonance (SPR), 11 electrochemiluminescence (ECL), 12−15 and photoelectrochemistry (PEC), 16−18 electrochemical biosensors have received much more attention due to their simplicity, cost-effectiveness, portability, and high sensitivity and selectivity. 19−22 For the specific capture of target glycoproteins, molecularly imprinted polymers (MIPs), 23 antibodies, 24,25 and nucleic acid aptamers 26−29 chemically synthesized and hold the merits of easy modification, high selectivity and affinity, low cost, and high stability.…”

mentioning

confidence: 99%

Boronate Affinity-Based Electrochemical Aptasensor for Point-of-Care Glycoprotein Detection

et al. 2022

Anal. Chem.

View full text Add to dashboard Cite

As a class of oligosaccharide chain-containing proteins, glycoproteins are of great value in screening and early diagnosis of malignant tumors and other major diseases. Herein, we report a universal boronate affinity-based electrochemical aptasensor for point-of-care glycoprotein detection. Aptasensing of glycoproteins involves the specific recognition and capture of target glycoproteins by end-tethered nucleic acid aptamers and the site-specific labeling of ferrocene tags via the phenylboronic acid (PBA)-based boronate affinity interactions because the cis-diol sites of oligosaccharide chains on glycoproteins can selectively react with the PBA receptor groups to form cyclic phenylborates in aqueous basic media. Due to the presence of hundreds to thousands of cis-diol sites on a glycoprotein, a large number of ferrocene tags can be recruited for the signal-on aptasensing of glycoproteins at a low-abundance level, eliminating the need for extra amplification strategies. As a result, the boronate affinity-based electrochemical aptasensor is highly sensitive and selective for glycoprotein detection and tolerant to the false-positive results. The detection limit for α-fetoprotein (AFP) is 0.037 ng/mL, with a linear response ranging from 0.1 to 100 ng/mL. In addition to the merits of simple operation, short assay time, and low detection cost, the aptasensor is applicable to the detection of glycoproteins in serum samples and the point-of-care detection using disposable flexible electrodes. Overall, this work provides a universal and promising platform for the point-of-care detection of glycoproteins, holding great potential in screening and early diagnosis of glycoprotein-related malignant tumors and other major diseases.

show abstract

mentioning

confidence: 99%

Boronate Affinity-Based Electrochemical Aptasensor for Point-of-Care Glycoprotein Detection

et al. 2022

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…Surface plasmon resonance (SPR) is a useful method, which can provide optical and label free detection of target analytes. The SPR detection method has many advantages, such as a low production cost, high detection accuracy and sensitivity, and has been successfully applied to cancer biomarkers and virus detection [40,41]. In 2019, Liu et al, used nanoparticle and microfluidic technologies to realize the SPR detection of the target protein.…”

Section: Advantages Of Microfluidic Poc Devices In Medical Laboratorymentioning

confidence: 99%

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Yang

Zhang

et al. 2022

Sensors

View full text Add to dashboard Cite

The early diagnosis of infectious diseases is critical because it can greatly increase recovery rates and prevent the spread of diseases such as COVID-19; however, in many areas with insufficient medical facilities, the timely detection of diseases is challenging. Conventional medical testing methods require specialized laboratory equipment and well-trained operators, limiting the applicability of these tests. Microfluidic point-of-care (POC) equipment can rapidly detect diseases at low cost. This technology could be used to detect diseases in underdeveloped areas to reduce the effects of disease and improve quality of life in these areas. This review details microfluidic POC equipment and its applications. First, the concept of microfluidic POC devices is discussed. We then describe applications of microfluidic POC devices for infectious diseases, cardiovascular diseases, tumors (cancer), and chronic diseases, and discuss the future incorporation of microfluidic POC devices into applications such as wearable devices and telemedicine. Finally, the review concludes by analyzing the present state of the microfluidic field, and suggestions are made. This review is intended to call attention to the status of disease treatment in underdeveloped areas and to encourage the researchers of microfluidics to develop standards for these devices.

show abstract

“…Biosensors enable a combination of bioactive materials and a corresponding transducer for the determination of a specific chemical or biological substance, mainly including electrical types and optical types. The optical biosensors based on fluorescence spectroscopy, surface plasmon resonance (SPR), dynamic light scattering (DLS), and Raman scattering (RS) have been utilized for the detection of bladder cancer biomarkers [17][18][19]. The above methods usually require multiple sample preparation or processing steps, and still depend on sophisticated instrument for measurement, restricting the field application.…”

Section: Introductionmentioning

confidence: 99%

Electrochemical Biosensor Employing Bi2S3 Nanocrystals-Modified Electrode for Bladder Cancer Biomarker Detection

et al. 2022

View full text Add to dashboard Cite

Bladder cancer is a kind of malignant tumor with high incidence in the urinary system, complex pathogenic causes, and the high recurrence rate. Biosensors capable of rapid, on site, and accurate bladder cancer diagnosis method continue to be lacking. Here, the electrochemical biosensor for detecting cytokeratin 18 (CK18, bladder cancer biomarker) was constructed based on the chemically modified electrode (CME). The work electrode (WE) was modified by bismuth sulfide semiconductor nanocrystals (Bi2S3 NCs), and then immobilized with CK18 antibodies and blocking agents to complete the electrode preparation. The results indicated that the interface of a flexible carbon electrode with Bi2S3 NCs film was steady with reliable charge transfer capability. With the large specific area and quantum size effect, the proposed sensor could detect CK18 antigen protein with an ultralow detection limit of 1.87 fM (fmol L−1) and wide linear dynamic range of 1–1000 pg mL−1, respectively. Detecting results could be read in less than 30 s with the portable, planar flexible CME. The sensitive and specific electrochemical biosensor possessed the characteristics of rapidity, ease-of-use, and non-invasive detection, indicating the application prospect in the early screening of bladder cancer and other diseases.

show abstract

Advances in surface plasmon resonance–based biosensor technologies for cancer biomarker detection

Cited by 82 publications

References 117 publications

Boronate Affinity-Based Electrochemical Aptasensor for Point-of-Care Glycoprotein Detection

Boronate Affinity-Based Electrochemical Aptasensor for Point-of-Care Glycoprotein Detection

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Electrochemical Biosensor Employing Bi2S3 Nanocrystals-Modified Electrode for Bladder Cancer Biomarker Detection

Contact Info

Product

Resources

About